We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · March 02, 2021

Survival and Biomarker Analyses From the OpACIN Immunotherapy Trials in Stage III Melanoma

Nature Medicine


Additional Info

Nature Medicine
Survival and Biomarker Analyses From the OpACIN-neo and OpACIN Neoadjuvant Immunotherapy Trials in Stage III Melanoma
Nat. Med. 2021 Feb 01;27(2)256-263, EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw, JM Versluis, O Krijgsman, P Dimitriadis, K Sikorska, BA van de Wiel, H Eriksson, M Gonzalez, A Torres Acosta, LG Grijpink-Ongering, K Shannon, JBAG Haanen, J Stretch, S Ch'ng, OE Nieweg, HA Mallo, S Adriaansz, RM Kerkhoven, S Cornelissen, A Broeks, WMC Klop, CL Zuur, WJ van Houdt, DS Peeper, AJ Spillane, ACJ van Akkooi, RA Scolyer, TNM Schumacher, AM Menzies, GV Long, CU Blank

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading